KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Prenatal Intravenous Iron and Child Growth: A Secondary Analysis of a Randomized Clinical Trial. PMID 41148141 · JAMA Netw Open · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. PMID 41124598 · Oncologist · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma. PMID 41123892 · JAMA Netw Open · 2025-Oct-01 This is a secondary, retrospective cohort analysis evaluating racial disparities across multiple historical GOG RCTs. It is not a primary report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention as the key element. The phase of the underlying trials is not explicitly stated in the provided metadata, and the report does not focus on a specific drug intervention, making it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preserved Cognitive Function After Statin Administration During Cancer Treatment With Doxorubicin: A Secondary Analysis of a Randomized Clinical Trial. PMID 41118164 · JAMA Netw Open · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points. PMID 41066125 · JAMA Netw Open · 2025-Oct-01 The study is an independent decision-analytic model estimating outcomes of a planned screening trial, not a clinical trial report. It does not involve a drug intervention, and its outcomes (late-stage incidence reductions, mortality reductions over fixed periods) are not time-to-event endpoints in the required sense. The trial phase is not specified.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC. PMID 41056430 · Oncologist · 2025-Oct-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials. PMID 41055581 · Int J Neuropsychopharmacol · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials. PMID 41034823 · BMC Cancer · 2025-Oct-01 The study meets most criteria but fails the critical time-to-event endpoint requirement. The primary efficacy outcome is the proportion of patients without nausea in the overall phase (0-120h), which is a categorical response rate, not a time-to-event measure like OS, PFS, or similar. No Kaplan-Meier curves or hazard ratios are mentioned.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study. PMID 41032725 · J Med Internet Res · 2025-Oct-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase II trial of radiotherapy plus Huachansu in elderly or chemotherapy-ineligible patients with locally advanced esophageal squamous cell carcinoma. PMID 41021440 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A prospective study of serum folate levels in patients with solid tumors treated with olaparib. PMID 41014151 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of a whole food plant-based dietary intervention on cancer progression and inflammatory markers. PMID 40973844 · Oncologist · 2025-Oct-01 The study is a randomized trial in metastatic breast cancer reporting original results, but it lacks a primary/key secondary time-to-event efficacy endpoint (only biomarker changes are reported), the intervention is dietary (not a drug), and it does not explicitly establish a Phase III/IIIb or Phase II/III status.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SUNRISE-CRC: a randomized phase II study of high-dose intermittent sunitinib versus trifluridine/tipiracil in metastatic colorectal carcinoma. PMID 40973474 · Oncologist · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dexmedetomidine for Analgesia in Nonintubated Patients With Traumatic Rib Fractures: A Randomized Clinical Trial. PMID 40900569 · JAMA Surg · 2025-Oct-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule of 177Lu-PSMA Molecular Radiotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT): Study Protocol. PMID 40876952 · J Nucl Med · 2025-Oct-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI). PMID 40876084 · Eur J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Secondary Analysis of a Randomized Clinical Trial. PMID 40875250 · JAMA Otolaryngol Head Neck Surg · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer. PMID 40850317 · Eur J Cancer · 2025-Oct-01 The record describes a randomized trial of a non-drug supportive care intervention (patient navigation with symptom monitoring) for advanced lung cancer. While it reports time-to-event endpoints (PFS, OS) as secondary outcomes, it does not meet the core criteria: (1) the trial phase is not specified as Phase III/IIIb or Phase II/III (sample size of 150 suggests an earlier phase), and (2) the intervention is not a drug-containing intervention. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial. PMID 40839373 · JAMA Oncol · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants. PMID 40833801 · Pediatr Infect Dis J · 2025-Oct-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A novel approach to assess the prognostic value of toxicity profiles in gastric cancer patients undergoing preoperative treatment. PMID 40818318 · Eur J Cancer · 2025-Oct-01 The record describes a secondary/prognostic analysis of a randomized trial (CRITICS), not the primary or definitive efficacy report. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. While oncology, human, randomized, drug intervention, and time-to-event endpoints are present, the study is not an original primary result of a definitive-phase trial comparing interventions for efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. PMID 40810951 · JAMA Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Bacterial Decolonization With Mupirocin Ointment for Acute Radiation Oral Mucositis Prevention: A Phase 3 Randomized Clinical Trial. PMID 40773220 · JAMA Oncol · 2025-Oct-01 The study is an eligible Phase 3 randomized oncology trial with a drug intervention and original primary results, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is the incidence of severe acute radiation oral mucositis (grade ≥3 AROM), which is a categorical toxicity/outcome measure, not a time-to-event measure like OS, PFS, DFS, etc. There is no mention of Kaplan-Meier analysis or hazard ratio.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial. PMID 40758358 · JAMA Intern Med · 2025-Oct-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial. PMID 40736443 · Clin Cancer Res · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders. PMID 40705465 · J Clin Invest · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved. PMID 40626521 · Dis Colon Rectum · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. PMID 40579995 · Neuro Oncol · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term outcomes of single-incision laparoscopic surgery for colorectal cancer, a single-center, open-label, randomized controlled trial. PMID 40549445 · Int J Surg · 2025-Oct-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial. PMID 40490846 · Int J Cancer · 2025-Oct-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets. PMID 40489668 · Rheumatology (Oxford) · 2025-Oct-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomised trial on treatment of vaginal high-grade squamous intraepithelial lesion: Self-administered vaginal imiquimod and laser vaporisation. PMID 40454918 · Int J Cancer · 2025-Oct-01 Eligibility criteria require an original Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). While the record describes a randomized trial with a drug intervention (imiquimod) in an oncology setting (vaginal HSIL), it fails on two key grounds: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III; the abstract and metadata do not specify a phase, and the deterministic review correctly flags 'phase3: false'. 2) The primary efficacy endpoint is histological regression rate (a categorical outcome), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier or HR. The abstract does not mention any time-to-event analysis or survival curves. Therefore, it does not meet the mandatory criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of Outcomes of Microsurgical Breast Reconstruction after Premastectomy and Postmastectomy Radiation Therapy. PMID 40366003 · J Am Coll Surg · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Acute and Late Radiation-Related Toxicity After Treatment of Locally Advanced Rectal Cancer With Intensity Modulated Radiation Therapy Compared With 3-Dimensional Conformal Radiation Therapy in the RAPIDO Trial. PMID 40354950 · Int J Radiat Oncol Biol Phys · 2025-Oct-01 The record describes a Phase III randomized trial (RAPIDO) with a drug intervention, but the primary endpoints are acute and late radiation-related toxicity and treatment compliance, analyzed as binary outcomes with logistic regression. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier curves or hazard ratios. Therefore, it is ineligible for this KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term risk of major cardiac events in breast cancer patients treated with intensity-modulated and 3-dimensional conformal radiotherapy: Secondary analysis of a randomized clinical trial. PMID 40345828 · Int J Cancer · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program. PMID 40036804 · Inflamm Bowel Dis · 2025-Oct-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. PMID 39773524 · Am J Gastroenterol · 2025-Oct-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials. PMID 41416027 · J Clin Aesthet Dermatol · 2025-Oct 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A machine learning approach for radiation pneumonitis prediction in elderly esophageal cancer patients by integrating baseline computed tomography radiomics, dosiomics, and clinical characteristics. PMID 41333544 · Phys Imaging Radiat Oncol · 2025-Oct This is a secondary predictive modeling study based on a Phase III trial, not a primary report of the trial's efficacy results. The endpoint is a toxicity (radiation pneumonitis), not a time-to-event efficacy endpoint (OS, PFS, etc.). No drug intervention is described.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Low-Dose Colchicine in Patients With Type 2 Diabetes With Recent Myocardial Infarction in the Colchicine Cardiovascular Outcome Trial (COLCOT): A Systematic Review. PMID 41322854 · Cureus · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study. PMID 41250682 · Pulm Circ · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase. PMID 41181851 · EClinicalMedicine · 2025-Oct The record describes a randomized Phase III trial of umbilical cord-derived mesenchymal stromal cells for recessive dystrophic epidermolysis bullosa, a non-oncologic genetic disorder. While it is a randomized trial with original results, it does not meet the core eligibility criteria: it is not an oncology study, it involves a cell therapy (not a conventional drug), and the primary endpoint (EBDASI) is not a time-to-event efficacy measure.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial. PMID 41181826 · EClinicalMedicine · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema. PMID 41181467 · Ann Med Surg (Lond) · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Development of a Novel Machine Learning Method for Estimation of Life-Long Chronic Disease Progression and Its Application to Type 2 Diabetes. PMID 41127917 · Clin Transl Sci · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial. PMID 41123227 · Cancer Med · 2025-Oct The study is an open-label, non-randomized pragmatic clinical trial. It is not randomized, and the phase is not explicitly stated as Phase III/IIIb or Phase II/III. While it reports time-to-event endpoints (OS, PFS), the primary endpoint was safety, and it does not meet the core criteria of a randomized Phase III/IIIb or Phase II/III trial with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nanoliposomal Irinotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum-Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. PMID 41117518 · Cancer Med · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine. PMID 41117170 · J Med Virol · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. PMID 41100115 · Expert Opin Biol Ther · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial. PMID 41091746 · Cephalalgia · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -